Singapore, May 08, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, proudly announces the successful completion of its acquisition of CK Health Plus Sdn Bhd (“CK Health”) today.
Key Points:
- Singapore, May 08, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, proudly announces the successful completion of its acquisition of CK Health Plus Sdn Bhd (“CK Health”) today.
- CK Health is a direct seller of holistic wellness consumer products in Malaysia, committed to delivering high-quality products that promote holistic well-being.
- With this acquisition, EUDA gains access to CK Health's distribution network, customer base, and expertise in the wellness industry.
- EUDA's CEO Dr Kelvin Chen expressed excitement about the acquisition, stating, "We are thrilled to welcome CK Health into the EUDA family.
SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it will acquire CK Health Plus Sdn Bhd (“CK Health”), a direct seller of holistic wellness consumer products in Malaysia.
Key Points:
- SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it will acquire CK Health Plus Sdn Bhd (“CK Health”), a direct seller of holistic wellness consumer products in Malaysia.
- Established in Malaysia in 2023, CK Health is a direct seller of holistic wellness consumer products through its online platform and member network.
- CK Health’s products leverage non-invasive therapies to make holistic healthcare accessible for everyone using advanced technologies.
- Through CK Health, EUDA will license bioenergy cabins to partners such as spas, beauty salons, and confinement centers and will distribute Yoroyal’s consumer products through direct selling, e-commerce platforms, and retail outlets.
Retrieved on:
Tuesday, January 16, 2024
Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Nasdaq on January 9, 2024 indicating that the Company had failed to maintain a minimum market value of listed securities of $35 million over the previous 30 consecutive business days (the “MVLS Requirement”) as required by the Nasdaq Listing Rule 5550(b)(2).
Key Points:
- Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Nasdaq on January 9, 2024 indicating that the Company had failed to maintain a minimum market value of listed securities of $35 million over the previous 30 consecutive business days (the “MVLS Requirement”) as required by the Nasdaq Listing Rule 5550(b)(2).
- On January 16, 2024, the Company received a written notice from Nasdaq stating that the Company’s Market Value of Listed Securities has been $35 million or greater for ten consecutive business days from January 2 to January 16, 2024, and therefore the Company has regained compliance with the MVLS requirement for continued listing on the Nasdaq Capital Market.
- For investor and media inquiries, please contact:
Retrieved on:
Tuesday, January 16, 2024
Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on January 9, 2024 indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of $35 million over the previous 30 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).
Key Points:
- Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on January 9, 2024 indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of $35 million over the previous 30 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).
- In order to regain compliance with Nasdaq Listing Rule 5550(b)(2), the Market Value of Listed Securities of the Company must close at $35,000,000 or more for a minimum of ten consecutive business days during the MVLS Compliance Period.
- In the event that the Company does not regain compliance with Nasdaq Listing Rule 5550(b)(2) within the MVLS Compliance Period, Nasdaq will provide notice to the Company that its listed securities will be subject to delisting.
- In the event of such notification, the Company may appeal Nasdaq’s determination to delist its securities, but there can be no assurance that Nasdaq would grant the Company’s request for continued listing.
Retrieved on:
Thursday, October 5, 2023
Under the letter of intent, TheoremRx would merge with a subsidiary of EUDA.
Key Points:
- Under the letter of intent, TheoremRx would merge with a subsidiary of EUDA.
- “The proposed merger represents an exciting opportunity for EUDA to bolster its market position through the strategic combination with a biotech company with immediate growth and innovation opportunity,” said Dr. Kelvin Chen, Founder and CEO of EUDA.
- “We believe TheoremRx has strong access to capital and a robust pipeline of compounds addressing high-demand unmet therapeutic areas with near-term inflection points.
- There can be no assurance that the merger will be completed or that the proposed terms set forth in the letter of intent will remain unchanged.
Retrieved on:
Friday, September 22, 2023
Singapore, Sept. 22, 2023 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on August 10, 2023 indicating that the Company was not in compliance with the $1.00 Minimum Bid Price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).
Key Points:
- Singapore, Sept. 22, 2023 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on August 10, 2023 indicating that the Company was not in compliance with the $1.00 Minimum Bid Price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).
- On September 14, 2023, the Company received a written notice from Nasdaq stating that the closing bid price of the Company’s common stock has been at $1.00 per share or greater for 10 consecutive business days from August 30 to September 13, 2023, and therefore the Company has regained compliance with the $1.00 Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market.
- On September 20, 2023, the Company received a written notice from Nasdaq stating that the Company’s market value of listed securities has been $35 million or greater for 10 consecutive business days from September 6 to September 19, 2023, and therefore the Company has regained compliance with the MVLS Requirement for continued listing on The Nasdaq Capital Market.
- All matters relating to the Company’s previous non-compliance with the Nasdaq Capital Market’s continued listing rules are now closed.
The Notice does not result in the immediate delisting of the Company’s securities from The Nasdaq Capital Market.
Key Points:
- The Notice does not result in the immediate delisting of the Company’s securities from The Nasdaq Capital Market.
- The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share and, based upon the closing bid price of the Company’s securities for the 30 consecutive business days for the period ending August 9, 2023, the Company no longer meets this requirement.
- The Notice indicated that the Company will be provided 180 calendar days in which to regain compliance.
- The Company intends to monitor the closing bid price of its securities and is considering its options to regain compliance with the Bid Price Requirement.
Singapore, Aug. 04, 2023 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a notice (the “MVLS Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company’s listed securities failed to comply with the $35 million market value of listed securities (“Market Value of Listed Securities”) requirement for continued listing on the Nasdaq Capital Market in accordance with Nasdaq Listing Rule 5550(b)(2) based upon the Company’s Market Value of Listed Securities for the 30 consecutive business days prior to the date of the MVLS Notice.
Key Points:
- Singapore, Aug. 04, 2023 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”) received a notice (the “MVLS Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company’s listed securities failed to comply with the $35 million market value of listed securities (“Market Value of Listed Securities”) requirement for continued listing on the Nasdaq Capital Market in accordance with Nasdaq Listing Rule 5550(b)(2) based upon the Company’s Market Value of Listed Securities for the 30 consecutive business days prior to the date of the MVLS Notice.
- In order to regain compliance with Nasdaq Listing Rule 5550(b)(2), the Market Value of Listed Securities of the Company must close at $35,000,000 or more for a minimum of ten consecutive business days during the MVLS Compliance Period.
- The Company does not currently meet the other continued listing standards of the Nasdaq Capital Market.
- In the event that the Company does not regain compliance with Nasdaq Listing Rule 5550(b)(2) within the MVLS Compliance Period, or regain compliance with Nasdaq Listing Rule 5550(b)(1) or Nasdaq Listing Rule 5550(b)(3), Nasdaq will provide notice to the Company that its listed securities will be subject to delisting.
SINGAPORE, April 10, 2023 /PRNewswire/ -- EUDA Health Holdings Limited (the "Company" or "EUDA") (NASDAQ: EUDA, EUDAW), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, announced today that it received a delinquency notification letter ("Notice") from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") on April 5, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the "Form 10-K").
Key Points:
- SINGAPORE, April 10, 2023 /PRNewswire/ -- EUDA Health Holdings Limited (the "Company" or "EUDA") (NASDAQ: EUDA, EUDAW), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, announced today that it received a delinquency notification letter ("Notice") from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") on April 5, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the "Form 10-K").
- Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC").
- The Notice states that the Company has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rules.
- The Notice has no immediate impact on the listing of the Company's common stock, which will continue to trade on Nasdaq under the symbol "EUDA".
Retrieved on:
Wednesday, November 23, 2022
P.C,
Growth,
Business architecture,
Health,
Virgin Islands,
History,
Probability,
Risk,
Patient,
Prospectus,
Emergency,
Ecosystem,
Failure,
Acquisition,
Security (finance),
Risk management,
LAX Singapore, Nov. 23, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the Company or LAX) (NASDAQ: LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the Business Combination) with EUDA Health Ltd (EUDA Health),a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare.
Key Points:
- Singapore, Nov. 23, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the Company or LAX) (NASDAQ: LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the Business Combination) with EUDA Health Ltd (EUDA Health),a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare.
- The combined company will operate under the name EUDA Health Holdings Limited (NASDAQ: EUDA) and will be led by Founder and Chief Executive Officer Dr. Kelvin Chen.
- James Meng Dong Tan, CEO & Director of 8i Acquisition 2 Corp., commented: On behalf of LAXs leadership and our investors, we would like to congratulate the EUDA Health team on a successful business combination.
- This document includes forward-looking statements within the meaning of the U.S. federal securities laws with respect to the Business Combination transaction between LAX and EUDA Health.
